Is There Room for Second-Line Treatment of Pleural Malignant Mesothelioma?

JAMA Oncol. 2017 Sep 1;3(9):1170-1171. doi: 10.1001/jamaoncol.2016.6135.

Authors

Alfredo Addeo¹, Lucio Buffoni², Massimo Di Maio³

Affiliations

¹ Oncology Department, Bristol Cancer Centre, Bristol, England.
² Department of Oncology, San Luigi Hospital, University of Turin, Turin, Italy.
³ Department of Oncology, Mauriziano Hospital, University of Turin, Turin, Italy.

PMID: 28114625
DOI: 10.1001/jamaoncol.2016.6135

No abstract available

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Clinical Decision-Making
Evidence-Based Medicine
Humans
Lung Neoplasms / diagnosis
Lung Neoplasms / drug therapy*
Lung Neoplasms / mortality
Mesothelioma / diagnosis
Mesothelioma / drug therapy*
Mesothelioma / mortality
Mesothelioma, Malignant
Patient Selection
Pemetrexed / adverse effects
Pemetrexed / therapeutic use*
Pleural Neoplasms / diagnosis
Pleural Neoplasms / drug therapy*
Pleural Neoplasms / mortality
Progression-Free Survival
Randomized Controlled Trials as Topic
Time Factors

Substances

Antineoplastic Agents
Pemetrexed